POCT Respiratory Virus
[POCT Respiratory Virus]
EPTIS factsheet 1144039 | Last revision 2024-10-01 | URL: https://www.eptis.bam.de/pts1144039 https://www.eptis.bam.de/pts1144039
| PT provider | ||||||||||||||||
| PT provider | Weqas Weqas | |||||||||||||||
| Based in | United Kingdom | |||||||||||||||
| Language(s) | English | |||||||||||||||
| Remarks | The viral testing targets in POCT platforms can be single, dual or multiplex; the most common being targeted for Influenza A (and subtypes) Influenza B, SARS-Cov-2, and Respiratory Syncytial Virus (RSV). Platforms tend to be based on nucleic acid amplification technologies (NAAT), which generally have improved sensitivity compared to first generation Antigen based devices. Two liquid human serum samples are distributed monthly over an extended autumn and winter season with a minimum of 16 samples distributed over the year covering a wide viral load. The samples consist of inactivated virus in a stabilising buffer which may contain Influenza A (either / both H1N1 and H3N2 subtypes), influenza B, RSV, SARS-Cov-2 or no virus. A range of differing viral loads are distributed including samples with single or multiple viruses. The mean Threshold Cycle value (Ct) is also provided for the Real-time PCR (polymerase chain reaction) methods as an estimate of the viral load, however data collected from participants on this parameter is not scored. The programme assesses the ability of the laboratory / POCT site to correctly identify the virus (es) present in the sample, the sensitivity and specificity of the test at the individual site and the overall performance of the method. The qualitative scores broadly reflect clinical importance, where the manufacturer quoted sensitivities of the methods / devices, are also considered. A correct identification of the virus (es) is given a score of 0. A sliding scale score of between 3 and 5 is assigned for incorrectly identified results, where 5 represented a gross misclassification of the result. Key Features: - Liquid stable samples are supplied ready to use; no pre-analytical preparation is required. - Qualitative reporting for SARS-CoV-2 Ag (RNA), Influenza A, Influenza B and RSV available. For more information: https://www.weqas.com/services/poct-eqa/poct-respiratory-virus/ or contact@weqas.com | |||||||||||||||
| Keywords | ||||||||||||||||
| Product groups |
Health care / medical devices
|
|||||||||||||||
| Testing fields |
Medical analysis
|
|||||||||||||||
| Technical details | ||||||||||||||||
|
||||||||||||||||
| Aims of the PT scheme | ||||||||||||||||
| Target group of participants | A number of POCT devices used for rapid screening of respiratory viral infections including seasonal influenza are now widely available. | |||||||||||||||
| Linked to specific legislation / standards | ISO/IEC 17043 | |||||||||||||||
| Additional, subsidiary aims | validation of testing methods | |||||||||||||||
| Number of participants | ||||||||||||||||
| Accredited or otherwise reviewed by a 3rd party |
Accredited by UKAS on the basis of ISO/IEC 17043 |
|||||||||||||||
| Operation is commissioned / requested by | ||||||||||||||||
| Fees and frequency | ||||||||||||||||
| Participation fee | https://www.weqas.com/participantzone/subscription-charges/ | |||||||||||||||
| Regularly operated | Yes (Frequency: Bimonthly. Samples: 2 x 1.0mL) | |||||||||||||||
| Year of first operation | 2021 | |||||||||||||||
| Contact details of the PT provider | ||||||||||||||||
| Provider | Contact person | |||||||||||||||
|
Weqas
Unit 6, Parc Ty Glas CF14 5DU Cardiff United Kingdom Phone: 44 (0) 2920 314750 Fax: Web: http://www.weqas.com http://www.weqas.com |
Laura Lloyd-Lewis
Phone: 44 (0) 29218 32884 Fax: Email: laura.lloyd-lewis@wales.nhs.uk laura.lloyd-lewis@wales.nhs.uk |
|||||||||||||||
If you find any mistakes please contact the responsible EPTIS coordinator in United Kingdom,
Mr Savvas Xystouris.
Mr Savvas Xystouris.